Sohini Das

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Medical device makers have urged a shift to a fair pricing model amid concerns over inflated MRPs, even as stakeholders remain divided on pricing practices in healthcare

India's pharma and healthcare firms may post steady Q4 revenue growth, but weak US generics and rising costs are likely to keep margins under pressure

Maruti Suzuki phases out Ignis amid weak demand, even as strong bookings and production constraints lead to supply shortages in Wagon R and S-Presso models

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Despite modest profit growth, SML Mahindra reports strong revenue gains and outlines plans to expand market share and enter electric bus segment

Auto companies are likely to post strong volume-led growth in Q4FY26, but rising input costs and commodity inflation are beginning to weigh on margins across segments

India's pharmaceutical industry remains dependent on China for bulk drugs, particularly fermentation-based antibiotics, vitamins and intermediates

Replacement demand recovery is expected to support near-term growth, while rising electrification and changing consumer preferences may drive scooters to overtake motorcycles in the long run

Ather plans to reduce aluminium content in scooters to cut costs and improve margins, with up to 15 per cent savings expected on its upcoming EL platform

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Orbicular Pharma and Apotex secure tentative US FDA approval for generic Ozempic, marking entry into fast-growing semaglutide market pending patent clearance

Automaker aims to double India market share with new models, alternate fuel push and potential entry into sub-4 metre SUV segment by 2030

Strong demand for top-end luxury cars and EVs helps the carmaker post 5% sequential growth despite volatility, currency pressure and rising import costs

Indian pharma market's growth was led more by price increases that an uptick in consumption

VinFast and BYD outpace the US EV giant with sharper pricing, faster localisation signals and wider networks, even as Tesla sticks to an import-led strategy

Kiran Mazumdar-Shaw urges IPO reforms, saying India's listing norms hinder biotech firms that need long R&D cycles before generating revenue

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Co says strong product mix, multi-powertrain strategy drive volume and market share gains

High base effect, weak pentup demand, and West Asia conflict to temper momentum